ArticleFrontiers in oncology2025
The presence of a fat layer after neoadjuvant chemotherapy as an indicator of prognosis in osteosarcoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the potential of magnetic resonance imaging (MRI) to monitor the response in patients with osteosarcoma receiving chemotherapy and to assess the correlation between the presence of a fat layer surrounding the tumor after neoadjuvant chemotherapy and prognosis. Methods: In total, 28 patients with osteosarcoma were included in this retrospective study. All patients underwent chemotherapy and surgery. MRI scans of the patients were evaluated before and after neoadjuvant chemotherapy. The prognostic factors included histological response and alkaline phosphatase (ALP) level. Relapse and survival at follow-up were defined as patient outcomes. The log-rank test was used to compare these factors with various MRI characteristics (e.g. change in maximum lesion length before and after chemotherapy, change in maximum edema, and fat layer presence after chemotherapy). Results: The median time of follow-up was 64.3 ± 41.5 months. The 3- and 5-year event-free survival rates were 75.0% and 67.9%, respectively. ALP levels after chemotherapy were associated with tumor necrosis (p = 0.01). Change in maximum lesion length [p = 0.044; odds ratio (OR) = 0.035; confidence interval (CI): 0.01-0.911] was a predictor of survival. Changes in edema on T2-weighted sequences (p = 0.979; OR = 0.989, CI: 0.437-2.242) were not significant. The presence of a fat layer (p = 0.013; OR = 0.000; confidence CI: 0.000-0.018) predicted good event-free survival. Conclusions: The presence of a fat layer correlated with good prognosis in patients with osteosarcoma. MRI characteristics in the early stages could help to inform decision-making about treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.